ALMDT Median Technologies

Median Technologies: Financial Communications Schedule for the First Half of 2025

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--

Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results:

 

Publication

   

Date

 

2024 results

   

April 29, 2025*

*Distribution after the close of trading

About Median Technologies: Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit .

EN
14/01/2025

Underlying

ALMDTMedian Technologies

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: Launch of EUR22m capital increase to unlock EIB f...

Median Technologies has launched a EUR22m capital increase via a public offering of shares with warrants (ABSA), priced at EUR1.66 (at ~18% discount to 20-day VWAP), with 78% of the deal already secured via existing and new investors. The raise aimed to i) meet the drawing conditions of the Tranche

ALMDT MEDIAN TECHNOLOGIES
5h / 43m 5h / 43m 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: EIB loan signed, tied to equity raise and debt re...

Friday post-market, Median announced the final sign of the EIB loan agreement of EUR37.5m, which has been structured in three tranches (EUR19m, EUR8.5m, EUR10m) and with several key conditions being set to access the first one. These include i) a capital increase of at least EUR16m (including issua

ALMDT MEDIAN TECHNOLOGIES
07/14/25 July 14, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: CE mark filing keep eyonis on track, US launch be...

Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b

ALMDT MEDIAN TECHNOLOGIES
07/02/25 July 2, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: eyonis LCS heads for FDA nod in Q3 2025

This morning, Median announced that it has submitted a 510(k) FDA filing for eyonis LCS, remaining on track with prior guidance and with a plausible clearance expected in Q3 2025. We are confident in a positive outcome, as the submission is underpinned by two pivotal studies—REALITY and RELIVE—whic

ALMDT MEDIAN TECHNOLOGIES
05/14/25 May 14, 2025 1 EN
Maria Vara
  • Maria Vara
ALMDT Median Technolo...

Median Technologies: FY24 wrap-up signals cost discipline, outlook rei...

Median Technologies released its audited FY 2024 results, which contain no surprises versus the unaudited data already disclosed in prior updates (see Q4 2024 and Q1 2025 notes). Revenue for the year came in at EUR22.9m (+3.3% YoY), fully driven by iCRO services, and the order backlog stood at EUR7

ALMDT MEDIAN TECHNOLOGIES
04/30/25 April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch